Chimeric Antigen Receptor T Cells As Living Therapeutics Targeting Senescence And Age-Related Diseases
Imagine a “living drug” that could target and remove the very cells contributing to aging and age-related diseases. Recent research has explored this exciting possibility by repurposing a powerful immunotherapy, previously successful in treating certain cancers, to combat the effects of aging. This innovative approach involves genetically reprogramming a type of immune cell, called a T cell, to become a highly specific “seek and destroy” agent.
These modified T cells, known as Chimeric Antigen Receptor (CAR) T cells, are engineered to recognize and eliminate senescent cells. Senescent cells are often referred to as “zombie cells” because they stop dividing but remain metabolically active, accumulating in tissues as we age and secreting harmful substances that drive chronic inflammation and contribute to conditions like obesity, diabetes, and organ fibrosis.
In studies using mice, these specially designed CAR T cells were able to effectively clear senescent cells by targeting a specific protein on their surface. The results were remarkable: treated mice showed significant improvements in health, including reduced body weight, better metabolism, and increased physical activity. What’s particularly promising is that a single treatment with these engineered cells provided long-lasting benefits, even preventing the onset of age-related metabolic decline when given to younger mice.
This breakthrough suggests a new frontier in medicine, moving beyond treating individual diseases to potentially intervening in the fundamental processes of aging itself. While traditional drugs aimed at senescent cells often require repeated doses, this “living drug” approach offers the potential for sustained therapeutic effects from a single administration, paving the way for transformative strategies to promote healthy aging.
Source: link to paper